Concepedia

Author

Rodrigo Dienstmann

Vall d'Hebron Institute of OncologyORCID

Also Known As

Dienstmann Rodrigo, Dienstmann, Rodrigo, Joan Carles, R Dienstmann, R. Dienstmann, RODRIGO DIENSTMANN, Rodrigo Dienstmann, Rodrigo Dientsmann, Sonia Serradell

648

Publications

19.9K

Citations

57

H-Index

61

Concepts

All Affiliations

Vall d'Hebron Institute of OncologyVall d'Hebron Hospital UniversitariUniversitat Autònoma de BarcelonaCentro de Investigación Biomédica en Red de CáncerVall d'Hebron Institut de Recerca
RD

About

Rodrigo Dienstmann is an author at Vall d'Hebron Institute of Oncology specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

33

7.1K

2

Public Health

4

4

122

3

Biostatistics

4

4

105

4

Engineering

2

2

95

5

Biomedical Engineering

1

1

17

Rodrigo Dienstmann

×

88

Publications

13.3K

Citations

45

H-Index

YearCitations

The consensus molecular subtypes of colorectal cancer

Justin Guinney, Rodrigo Dienstmann, Xin Wang,

Nature Medicine

2015

5K

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann,

Annals of Oncology

2018

728

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

Malachi Griffith, Nicholas C. Spies, Kilannin Krysiak,

Nature Genetics

2017

651

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

David Tamborero, Carlota Rubio-Pérez, Jordi Deu-Pons,

Genome Medicine

2018

534

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

David Tamborero, Carlota Rubio-Pérez, Ferran Muiños,

Clinical Cancer Research

2018

411

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann,

Journal of Clinical Oncology

2015

371

Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk,

Gastroenterology

2014

323

A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara,

EMBO Molecular Medicine

2018

263

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

Rodrigo Dienstmann, Guillermo Villacampa, Anita Sveen,

Annals of Oncology

2019

259

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Rodrigo Dienstmann, Mike J. Mason, Frank A. Sinicrope,

Annals of Oncology

2017

245

Page 1